Detailed view for this entity.
“Now, Viking is still a pre-revenue company, but the stock had a great year in 2025.”
“those drugs have shown really good clinical trial results. In fact, some analysts have called those results eye-catching.”
“that makes Viking an attractive acquisition target potentially if their upcoming trials continue to impress.”